We talk about Miyé
We are delighted to have been honored with some nice press coverage.
Find interviews, articles and podcasts.
MIYÉ ON TV
BEL & BIEN
Watch Caroline de Blignères talking about MiYé and the products on the show
Bel et Bien.
MIYÉ IN THE PRINT MEDIA
THE BODY OPTIMIST
Discover an article on THE BODY OPTIMIST magazine, about one of our best sellers, our hair serum.
GALA
Discover an article on GALA magazine, on how to avoid menopausal weight gain, with our intimate gel in the spotlight.
VERSION FEMINA
Discover an article on VERSION FEMINA magazine about one of our new products [MY] Perfecting Moisturizing Emulsion
ELLE
Discover ELLE magazine's article on our new [MY] Crème Déodorante Douce, our summer favorite.
VERSION FEMINA
Discover MiYé's commitments and products in the article published in VERSION FEMINA magazine.
VOICI
Discover an article on VOICI magazine, on the subject of salycilic acid, highlighting our perfecting emulsion.
LSA
More expensive than conventional,
the organic hygiene and beauty segment is facing a downturn. However, its players are confident about the future of a market that is more vital than ever for the planet.
LE JOURNAL D'ICI
Pierre Fabre Laboratories pursue their strategy of acquiring stakes in fast-growing start-ups
MONACO MATIN
Pierre fabre, a good friend of Antibes-based MiYé. This first capital increase will enable the company to accelerate its development while benefiting from the group's expertise.
NICE MATIN
Pierre Fabre, the world's second largest dermo-cosmetics company, has become MiYé's sole minority shareholder, alongside co-founders Caroline de Blignières and Anna Oualid.
LE JOURNAL D'ICI
Pierre Fabre Laboratories have announced their investment in Miyé, a start-up specializing in hormonal balance, "a major challenge to which dermo-cosmetics must be able to respond", according to the head of the dermo-cosmetics branch, Frédéric Ennabili.
branch, Frédéric Ennabili.
TRIBUNE BULLETIN
The Côte d'Azur-based start-up specializing in care products and dietary supplements to treat
treatment of female hormonal disorders has announced that the French group has acquired a stake in its capital, via its investment subsidiary Pierre Fabre Invest.
